Faculty Publications

Activity of the anti-IGF-IR antibody CP-751,871 in combinatiion with docetaxel as first-line treatment for castration resistant prostate cancer in a randomized Phase II trial

De Bono JS, Petrylak DP, Calvo E, Saad F, Hudes GR, Cooney MM, Pollak MN, Agus DB, Gillessen S, Scranton J

Activity of the anti-IGF-IR antibody CP-751,871 in combinatiion with docetaxel as first-line treatment for castration resistant prostate cancer in a randomized Phase II trial

2008;:178.

Abstract

Last updated on Saturday, November 21, 2009